The Impact of Smoking on Nivolumab Outcomes in Renal Cell Carcinoma: Real-World Data from the Turkish Oncology Group Kidney Cancer Consortium (TKCC).

IF 4.8 2区医学 Q1 ONCOLOGY

Oncologist Pub Date : 2025-06-27 DOI:10.1093/oncolo/oyaf186

Elif Sertesen Camoz, Hatice Bolek, Omer Faruk Kuzu, Saadet Sim, Hilal Karakaş, Serhat Sekmek, Murad Guliyev, Aysun Fatma Akkus, Selver Isık, Deniz Tural, Cagatay Arslan, Sema Sezgin Goksu, Ozlem Nuray Sever, Nuri Karadurmuş, Cengiz Karacin, Mustafa Ozguroglu, Mehmet Ali Nahit Sendur, Emre Yekedüz, Yüksel Ürün

{"title":"The Impact of Smoking on Nivolumab Outcomes in Renal Cell Carcinoma: Real-World Data from the Turkish Oncology Group Kidney Cancer Consortium (TKCC).","authors":"Elif Sertesen Camoz, Hatice Bolek, Omer Faruk Kuzu, Saadet Sim, Hilal Karakaş, Serhat Sekmek, Murad Guliyev, Aysun Fatma Akkus, Selver Isık, Deniz Tural, Cagatay Arslan, Sema Sezgin Goksu, Ozlem Nuray Sever, Nuri Karadurmuş, Cengiz Karacin, Mustafa Ozguroglu, Mehmet Ali Nahit Sendur, Emre Yekedüz, Yüksel Ürün","doi":"10.1093/oncolo/oyaf186","DOIUrl":null,"url":null,"abstract":"Background: The study aims to evaluate the effect of smoking status on treatment results in patients with metastatic renal cell carcinoma (RCC) treated with nivolumab in the second and following lines of therapy.Materials and method: The Turkish Oncology Group Kidney Cancer Consortium (TKCC) database was used to extract retrospective data from patients with metastatic RCC treated with nivolumab in the second line and beyond. Patients were evaluated according to their smoking status.Results: A total of 247 patients were evaluated. The majority of the current smokers were male (93.8%, p=0.002). Nivolumab is mainly used in the second-line therapy (84.2%). Median time to treatment failure (TTF) and median overall survival was shorter in patients with currently smoking (10.81 vs. 4.11 months, p<0.001 and 32.33 vs. 16.76 months, p<0.049, respectively). Multivariate analysis showed that current smoking status was an independent adverse factor on median TTF (HR 2.06 95% confidence interval (CI)= 1.20-3.54, p=0.009) and median OS (, HR 2.06, 95% CI=1.25-3.38, p=0.004) in metastatic RCC patients treated with nivolumab in the second line and beyond.Conclusion: Current smoking status is an independent adverse prognostic factor for both TTF and OS in patients with metastatic RCC treated with nivolumab in the second line and beyond.","PeriodicalId":54686,"journal":{"name":"Oncologist","volume":" ","pages":""},"PeriodicalIF":4.8000,"publicationDate":"2025-06-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Oncologist","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1093/oncolo/oyaf186","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"ONCOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Background: The study aims to evaluate the effect of smoking status on treatment results in patients with metastatic renal cell carcinoma (RCC) treated with nivolumab in the second and following lines of therapy.

Materials and method: The Turkish Oncology Group Kidney Cancer Consortium (TKCC) database was used to extract retrospective data from patients with metastatic RCC treated with nivolumab in the second line and beyond. Patients were evaluated according to their smoking status.

Results: A total of 247 patients were evaluated. The majority of the current smokers were male (93.8%, p=0.002). Nivolumab is mainly used in the second-line therapy (84.2%). Median time to treatment failure (TTF) and median overall survival was shorter in patients with currently smoking (10.81 vs. 4.11 months, p<0.001 and 32.33 vs. 16.76 months, p<0.049, respectively). Multivariate analysis showed that current smoking status was an independent adverse factor on median TTF (HR 2.06 95% confidence interval (CI)= 1.20-3.54, p=0.009) and median OS (, HR 2.06, 95% CI=1.25-3.38, p=0.004) in metastatic RCC patients treated with nivolumab in the second line and beyond.

Conclusion: Current smoking status is an independent adverse prognostic factor for both TTF and OS in patients with metastatic RCC treated with nivolumab in the second line and beyond.

查看原文本刊更多论文

吸烟对肾细胞癌Nivolumab结局的影响：来自土耳其肿瘤组肾癌联盟（TKCC）的真实世界数据。

背景：本研究旨在评估吸烟状况对转移性肾细胞癌（RCC）患者在接受纳武单抗二线及后续治疗时治疗结果的影响。材料和方法：使用土耳其肿瘤组织肾癌联盟（TKCC）数据库提取转移性肾癌患者的回顾性数据，这些患者在二线及以上接受了纳武单抗治疗。根据患者的吸烟状况进行评估。结果：共评估247例患者。目前吸烟者以男性居多（93.8%,p=0.002）。Nivolumab主要用于二线治疗（84.2%）。目前吸烟患者的中位治疗失败时间（TTF）和中位总生存期较短（10.81个月vs 4.11个月）。结论：目前吸烟状态是nivolumab二线及以上治疗的转移性RCC患者TTF和OS的独立不良预后因素。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Oncologist 医学-肿瘤学

CiteScore

10.40

自引率

3.40%

发文量

309

审稿时长

3-8 weeks

期刊介绍： The Oncologist® is dedicated to translating the latest research developments into the best multidimensional care for cancer patients. Thus, The Oncologist is committed to helping physicians excel in this ever-expanding environment through the publication of timely reviews, original studies, and commentaries on important developments. We believe that the practice of oncology requires both an understanding of a range of disciplines encompassing basic science related to cancer, translational research, and clinical practice, but also the socioeconomic and psychosocial factors that determine access to care and quality of life and function following cancer treatment.